Drugs / plocabulin
plocabulin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02533674 | Dec 2014 → Jul 2019 | cancer | PharmaMar | Completed | No outcome recorded |
| Phase 1 | NCT01299636 | Jan 2011 → Aug 2015 | cancer | PharmaMar | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03427268 | Jan 2018 → Feb 2019 | colorectal cancer | PharmaMar | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | plocabulin | “Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule network leading to mitosis.” PMID 39096398 ↗ Aug 2024 |
| Known as | J3.348.355D | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297636 ↗ |
| Known as | Plo | “Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule network leading to mitosis.” PMID 39096398 ↗ Aug 2024 |
| Known as | Plocabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297636 ↗ |
| Known as | Plocabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297636 ↗ |
| Known as | PM060184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02533674 ↗ |
| Modality | Small molecule | — CHEMBL4297636 ↗ |
| Route | Intravenous | “PM060184 administered intravenously (i.v.)” NCT01299636 ↗ |